Edition:
United Kingdom

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

1.81USD
8:38pm GMT
Change (% chg)

$-0.01 (-0.55%)
Prev Close
$1.82
Open
$1.83
Day's High
$1.91
Day's Low
$1.80
Volume
198,448
Avg. Vol
400,582
52-wk High
$3.84
52-wk Low
$0.93

Latest Key Developments (Source: Significant Developments)

Infinity Q3 loss per share $0.14
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Infinity Pharmaceuticals Inc ::Infinity provides company update and reports third quarter 2017 financial results.Q3 loss per share $0.14.Q3 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Q3 revenue $6.0 million.Q3 revenue view $14.7 million -- Thomson Reuters I/B/E/S.Infinity Pharmaceuticals Inc - ‍infinity expects net loss for 2017 to range from $40 million to $50 million​.Infinity Pharmaceuticals - ‍expects to end 2017 with a cash, cash equivalents and available-for-sale securities balance ranging from $40 million to $50 million​.  Full Article

Infinity Pharma Q2 earnings per share $1.05
Tuesday, 9 Aug 2016 

Infinity Pharmaceuticals Inc : Q2 earnings per share $1.05 . Q2 revenue $9.5 million . Infinity provides company update and reports second quarter 2016 financial results . Q2 earnings per share view $-0.89 -- Thomson Reuters I/B/E/S . Q2 revenue view $13.9 million -- Thomson Reuters I/B/E/S . Continuing to explore a broad range of strategic options for duvelisib, including a potential sale of program . "in parallel, company continues to advance key value drivers for duvelisib" . Infinity is also proceeding with its planned development of ipi-549 in multiple solid tumors .Duo study of duvelisib compared to ofatumumab in 319 patients with relapsed or refractory cll, will proceed to final analysis.  Full Article

Infinity Pharmaceuticals sees workforce restructuring completed by year-end
Tuesday, 28 Jun 2016 

Infinity Pharmaceuticals Inc : Expects to incur severance, benefits and related costs of about $8 million . Says currently expects clinical trial and related development close down costs to range from $5 million to $7 million . Says company expects related cash outlays to be paid during year ended December 31, 2016 - SEC filing .Expects workforce restructuring to be substantially completed by July 15, 2016 ; to be fully completed by December 31, 2016.  Full Article

Infinity regains worldwide rights to duvelisib; ends collaboration with AbbVie
Tuesday, 28 Jun 2016 

Infinity Pharmaceuticals Inc : Infinity undertakes restructuring of workforce . Infinity will also reduce its workforce by 58 percent . Says neither infinity nor abbvie have future financial obligations to other party . Exploring strategic options for program that could enable submission of global regulatory applications, commercialization for duvelisib . Says will not proceed with phase 1b/2 study of duvelisib in combination with venetoclax . Says ipi-549 is only investigational pi3k-gamma inhibitor in clinical development . Continuing to focus on filing nda for duvelisib with u.s. Food and drug administration (fda) in q4 of 2016 . Plans to seek feedback on dynamo data from fda . Strategic decisions include closing bravura, a phase 3 study of duvelisib, contempo, a phase 1b/2 study of duvelisib . Also expects to report topline data from duo, predicated on results of an interim analysis, in q3 of 2016 .Infinity regains worldwide rights to duvelisib following mutual agreement with abbvie to end collaboration.  Full Article

Infinity Pharmaceuticals expects to incur total restructuring costs of about $6 to $8 mln
Tuesday, 14 Jun 2016 

Infinity Pharmaceuticals Inc : Expects restructuring to be substantially completed by july 1, 2016 and to be fully completed by december 31, 2016 . Expects to incur total restructuring costs ranging from approximately $6 to $8 million . Expects to record a majority of restructuring charges as research and development expenses during three months ended june 30, 2016 . Currently expects $5 million in future cash outlays related to severance, benefits and related costs .Continuing to review potential impact of restructuring, unable to estimate any additional restructuring costs or charges at this time.  Full Article

Infinity Pharmaceuticals Inc reports topline results from DYNAMO(tm)
Tuesday, 14 Jun 2016 

Infinity Pharmaceuticals Inc : Majority of reported side effects were reversible and clinically manageable. . Infinity Pharmaceuticals Inc says updated 2016 financial guidance to be provided following resolution of strategic activities . Previous financial guidance for 2016 should no longer be relied upon . Investigational, oral, dual inhibitor of phosphoinositide-3-kinase (pi3k)-delta and pi3k-gamma met primary endpoint . Undertaking strategic restructuring that will close down its discovery research organization, or 21 percent of workforce . Infinity Pharmaceuticals Inc says previous financial guidance for 2016 should no longer be relied upon . Duvelisib demonstrated overall response rate (ORR) of 46 percent, among 129 patients with iNHL . Abbvie, co have also agreed to pause ABBVIE-sponsored phase 1b/2 study evaluating duvelisib in combination with venetoclax . Hoped treatment with duvelisib as monotherapy would have provided larger clinical benefit for advance indolent non-hodgkin lymphoma .Infinity reports topline results from DYNAMO(tm), a phase 2 monotherapy study of investigational molecule duvelisib in refractory indolent non-hodgkin lymphoma.  Full Article

Infinity Pharmaceuticals Inc reaffirms FY 2016 guidance
Tuesday, 23 Feb 2016 

Infinity Pharmaceuticals Inc:Expects revenue for FY 2016 to range from $225 million to $245 million.Expects net income for FY 2016 to range from $15 million to $35 million.  Full Article

Infinity Pharmaceuticals Inc gives FY 2016 guidance
Monday, 11 Jan 2016 

Infinity Pharmaceuticals Inc:Expects revenue for FY 2016 to range from $225 million to $245 million.Expects net income for 2016 to range from $15 million to $35 million.  Full Article

BRIEF-Infinity Pharmaceuticals reports phase 1 clinical and translational data for IPI-549

* ‍Reported phase 1 clinical and translational data for IPI-549, that targets immune-suppressive tumor macrophages​